Dominik Berthold

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


91 publications

En préparation | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
En préparation
 
Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy
Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bartolini Robin, Joo Victor, Mederos Nuria, Bouchaab Hasna, Demicheli Rita, Abdelhamid Karim, Ferahta Nabila et al..
[DOI][serval:BIB_818D0F24F67B]
2024
 
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Bossi A., Foulon S., Maldonado X., Sargos P., MacDermott R., Kelly P., Fléchon A., Tombal B., Supiot S., Berthold D. et al., 2024/11/23. Lancet, 404 (10467) pp. 2065-2076. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6F5FB33F22B3]
Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue.
Sobottka B., Vetter V., Banaei-Esfahani A., Nowak M., Lorch A., Sirek A., Mertz K.D., Brunelli M., Berthold D., de Leval L. et al., 2024/10. Modern pathology, 37 (10) p. 100558. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AD338AA8E2F7]
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.
Cloître M., Benkhaled S., Boughdad S., Schaefer N., Prior J.O., Zeverino M., Berthold D., Tawadros T., Meuwly J.Y., Martel P. et al., 2024/05/31. Cancers, 16 (11). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F69D11E34A2A]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
2023
 
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R., Rothschild S.I., Hayoz S., Bubendorf L., Özdemir B.C., Kiss B., Erdmann A., Aeppli S., Mach N., Strebel R.T. et al., 2023/11/20. Journal of clinical oncology, 41 (33) pp. 5131-5139. Peer-reviewed.
[DOI][Pmid][serval:BIB_A7A5826347FE]
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A.J., Omlin A., Berthold D., Beyer J., Burger I.A., Eberli D., Engeler D., Fankhauser C., Fischer S., Gillessen S. et al., 2023/08/15. Swiss medical weekly, 153 p. 40108. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6C5E890FD075]
 
Cancer de la prostate à l’ère de la médecine de précision : un nouvel horizon [Prostate cancer in the era of precision medicine: a new horizon]
Nguyen-Ngoc T., Berthold D., Normand C., 2023/05/17. Revue medicale suisse, 19 (827) pp. 950-956. Peer-reviewed.
[DOI][Pmid][serval:BIB_1F5EA2E82D9D]
Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M., Valerio M., Mampuya A., Rakauskas A., Berthold D., Tawadros T., Meuwly J.Y., Heym L., Duclos F., Vallet V. et al., 2023/04/01. The British journal of radiology, 96 (1145) p. 20220803. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB3AC2C2AFDE]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
2022
 
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.
Papachristofilou A., Bedke J., Hayoz S., Schratzenstaller U., Pless M., Hentrich M., Krege S., Lorch A., Aebersold D.M., Putora P.M. et al., 2022/11. The Lancet. Oncology, 23 (11) pp. 1441-1450. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_989E8E47D384]
 
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis E.J., Martin-Liberal J., Kristeleit R., Cho D.C., Blagden S.P., Berthold D., Cardin D.B., Vieito M., Miller R.E., Hari Dass P. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e004235. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D7C84C98BDB5]
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
James N.D., Clarke N.W., Cook A., Ali A., Hoyle A.P., Attard G., Brawley C.D., Chowdhury S., Cross W.R., Dearnaley D.P. et al., 2022/08/01. International journal of cancer, 151 (3) pp. 422-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A1169D8AF655]
 
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K., Foulon S., Carles J., Roubaud G., McDermott R., Fléchon A., Tombal B., Supiot S., Berthold D., Ronchin P. et al., 2022/04/30. Lancet, 399 (10336) pp. 1695-1707. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B29C8E2B2F13]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
 
Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
Mulvey A., Muggeo-Bertin E., Berthold D.R., Herrera F.G., 2022. Frontiers in immunology, 13 p. 859785. Peer-reviewed.
[DOI][Pmid][serval:BIB_DE34735C811E]
2021
Infirmière clinicienne de centre du cancer : l’expérience du Centre de la prostate du CHUV [Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]
Codeluppi C., Ninane F., Jolliet L., Glemarec P., Orcurto A., Rakauskas A., Tawadros T., Bosshard P., Eicher M., Herrera F. et al., 2021/12/01. Revue medicale suisse, 17 (761) pp. 2082-2085. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B3EF72B4777A]
A new method to visualize and to spare the ureters during SBRT for oligo metastatic patients.
Muggeo-Bertin E., Moeckli R., Vallet V., Berthold D., Godin S., Bourhis J., Herrera F.G., 2021/09. Technical innovations & patient support in radiation oncology, 19 pp. 7-10. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5205796889DB]
Swiss germ-cell cancer consensus recommendations.
Beyer J., Berthold D., Bode P.K., Cathomas R., Fankhauser C.D., Fischer S., Gillessen S., Gross T., Hermanns T., Honecker F. et al., 2021/08/23. Swiss medical weekly, 151 (33-34) pp. w30023. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_632D6763E6AD]
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A., Tawadros T., Lucca I., Herrera F., Bourhis J., Burruni R., Gomes M.N., Codeluppi C., Jolliet L., La Rosa S. et al., 2021/07. Investigative and clinical urology, 62 (4) pp. 416-422. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_11DA8B398364]
Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021]
Cisarovsky C., Latifyan S., Perrinjaquet C., Berthold D., Orcurto A., 2021/05/19. Revue medicale suisse, 17 (739) pp. 974-977. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_954186CA59D9]
Oncologie [2020 oncology update]
Dei Tos G., Galli Vareia I., Huber A., Wolf B., Diciolla A., Herrera Gomez R.G., Wagner D., Digklia A., Bouchaab H., Cristina V. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 201-205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_25D6152EB267]
2020
 
Behandlung des fortgeschrittenen Prostatakarzinoms
Templeton Arnoud J, Amram Marie-Laure, Berthold Dominik, Beyer Jrg, Blaser Samuel, Burger Irene A., Eberli Daniel, Gillessen Sommer Silke, Grobholz Rainer, Kng Marc et al., 2020/12/01. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. Peer-reviewed..
[DOI][serval:BIB_FF54607A317C]
 
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Goebell P.J., Ivanyi P., Bedke J., Bergmann L., Berthold D., Boegemann M., Busch J., Doehn C., Krege S., Retz M. et al., 2020/10. Future oncology, 16 (29) pp. 2307-2328. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_467B24623EBB]
 
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.
Martinez Chanza N., Werner L., Plimack E., Yu E.Y., Alva A.S., Crabb S.J., Powles T., Rosenberg J.E., Baniel J., Vaishampayan U.N. et al., 2020/10. European urology oncology, 3 (5) pp. 671-679. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5983599BD430]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][Pmid][serval:BIB_7B31C4DA5F5B]
2019
 
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
Necchi A., Mariani L., Lo Vullo S., Yu E.Y., Woods M.E., Wong Y.N., Harshman L.C., Alva A., Sternberg C.N., Bamias A. et al., 2019/03. European urology focus, 5 (2) pp. 242-249. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8DC541D54E75]
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A5A6B3310C5]
 
Oncologie [Oncology, what's new in 2018]
Latifyan S., Kakourou A., Ozdemir B., Zaman K., Vernadou A., Berthold D., Abdelhamid K., Bouchaab H., Peters S., Montemurro M. et al., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 78-81. Peer-reviewed.
[Pmid][serval:BIB_E686DFA1B1CC]
2018
 
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
Sonpavde G.P., Mariani L., Lo Vullo S., Raggi D., Giannatempo P., Bamias A., Crabb S.J., Bellmunt J., Yu E.Y., Niegisch G. et al., 2018/12. The Journal of urology, 200 (6) pp. 1207-1214. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4618A1755B27]
 
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Necchi A., Pond G.R., Smaldone M.C., Pal S.K., Chan K., Wong Y.N., Viterbo R., Sonpavde G., Harshman L.C., Crabb S. et al., 2018/12. European urology focus, 4 (6) pp. 937-945. Peer-reviewed.
[DOI][Pmid][serval:BIB_104CA95A4385]
 
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Sandmeier N., Rothschild S.I., Rothermundt C., Cathomas R., Schardt J., Berthold D., von Burg P., Müller B., Beyer J., Vogt D.R. et al., 2018/08. Clinical genitourinary cancer, 16 (4) pp. e711-e718. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BC44A699A59]
2017
Ablation du cancer primaire dans les néoplasies urologiques oligométastatiques : évidence ou vœux pieux ? [Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?]
Valerio M., Cerantola Y., Lucca I., Berthold D., Jichlinski P., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2083-2086. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3B730D56DD60]
Iterative Reconstructions in Reduced-Dose CT: Which Type Ensures Diagnostic Image Quality in Young Oncology Patients?
Pauchard B., Higashigaito K., Lamri-Senouci A., Knebel J.F., Berthold D., Verdun F.R., Alkadhi H., Schmidt S., 2017/09. Academic radiology, 24 (9) pp. 1114-1124. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D9286BF48739]
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Ritchie AWS, Amos C.L., Gilson C., Jones R.J. et al., 2017/07/27. The New England journal of medicine, 377 (4) pp. 338-351. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF2E19F79ACD]
 
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
Papazoglou D., Wannesson L., Berthold D., Cathomas R., Gillessen S., Rothermundt C., Hasler L., Winterhalder R., Barth A., Mingrone W. et al., 2017/06. Clinical genitourinary cancer, 15 (3) pp. e315-e323. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80EDD64A446F]
 
Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse.
Gössi F., Spahn M., Zweifel M., Panagiotis S., Mischo A., Stenner F., Hess U., Berthold D., Bargetzi M., Schardt J. et al., 2017/02. Bone marrow transplantation, 52 (2) pp. 334-336. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A7B320CEE17]
 
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A., Sonpavde G., Lo Vullo S., Giardiello D., Bamias A., Crabb S.J., Harshman L.C., Bellmunt J., De Giorgi U., Sternberg C.N. et al., 2017/02. European urology, 71 (2) pp. 281-289. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8625159D29]
2016
 
Médicaments usuels en médecine de premier recours et cancer de la prostate : quelle relation ? [Common medications and prostate cancer : what is the association ?]
Rakauskas A., Grilo N., M'Baya O., Jichlinski P., Valerio M., Berthold D., 2016/11/30. Revue medicale suisse, 12 (541) pp. 2068-2071. Peer-reviewed.
[Pmid][serval:BIB_A37D39541A4B]
Carcinome rénal métastatique, retour vers le futur.. [Metastatic renal cell carcinoma, back to the future]
Martins F., Berthold D., 2016/05/18. Revue medicale suisse, 12 (519) pp. 994-998. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_51ABC794800F]
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R., Ritchie A.W., Parker C.C., Russell J.M., Attard G. et al., 2016/03/19. Lancet (London, England), 387 (10024) pp. 1163-1177. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_2BB6C537D055]
Radiation Therapy after Radical Prostatectomy: Implications for Clinicians.
Herrera F.G., Berthold D.R., 2016. Frontiers In Oncology, 6 p. 117. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B2C625B19773]
 
The role of renal biopsy in small renal masses.
Burruni R., Lhermitte B., Cerantola Y., Tawadros T., Meuwly J.Y., Berthold D., Jichlinski P., Valerio M., 2016. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 10 (1-2) pp. E28-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E17D73E719CC]
2015
Cancer testiculaire: un modèle pour optimiser le suivi radiologique [Testicular cancer: a model to optimize the radiological follow-up].
Stebler V., Pauchard B., Schmidt S., Valerio M., De Bari B., Berthold D., 2015/05. Revue Médicale Suisse, 11 (475) pp. 1144-1148. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1E2A61B344CE]
 
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky M.D., Pal S.K., Chowdhury S., Harshman L.C., Crabb S.J., Wong Y.N., Yu E.Y., Powles T., Moshier E.L., Ladoire S. et al., 2015. Cancer, 121 (15) pp. 2586-2593.
[DOI][WoS][Pmid][serval:BIB_5411A0986DEE]
 
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.
Valdagni R., Van Poppel H., Aitchison M., Albers P., Berthold D., Bossi A., Brausi M., Denis L., Drudge-Coates L., De Santis M. et al., 2015. Critical Reviews In Oncology/hematology, 95 (2) pp. 133-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4372DDDB8B9B]
2014
 
Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M., Berthold D., 2014. Progress in tumor research, 41 pp. 98-112. Peer-reviewed.
[DOI][Pmid][serval:BIB_502F2CD856F8]
2013
 
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Horwich A., Parker C., de Reijke T., Kataja V., ESMO Guidelines Working Group, 2013/10. Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6 pp. vi106-14. Peer-reviewed.
[DOI][Pmid][serval:BIB_BE1E8D1D3846]
 
Prostate cancer: ESMO Consensus Conference Guidelines 2012.
Horwich A., Hugosson J., de Reijke T., Wiegel T., Fizazi K., Kataja V., Panel Members, European Society for Medical Oncology, 2013/05. Annals of oncology, 24 (5) pp. 1141-1162. Peer-reviewed.
[DOI][Pmid][serval:BIB_3E5CFB01FA34]
 
Centre de la prostate: une approche multidisciplinaire pour une prise en charge globale du patient [Prostate cancer center: a multidisciplinary approach to accurately manage patients with prostate cancer]
Tawadros T., Burruni R., Herrera F., Codeluppi C., Zurkinden C., Meuwly J.Y., Lhermitte B., Berthold D., 2013. Revue Médicale Suisse, 9 (409) pp. 2270-2, 2274.
[Pmid][serval:BIB_AA917B8978EC]
 
Immunothérapie: une nouvelle arme contre le cancer de la prostate [Immunotherapy: a therapeutic revolution against prostate cancer?].
Pracht M., Herrera F.G, Tawadros T., Berthold D., 2013. Revue Médicale Suisse, 9 (387) pp. 1070-1075. Peer-reviewed.
[Pmid][serval:BIB_872CCC33F242]
Simultaneous renal oncocytoma and lymphoma: interest of lymphadenectomy
Orcurto A., Lhermitte B., Sermier A., Berthold D., 2013. Case Reports In Urology, 2013 p. 729108. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_982F4C32C44B]
2012
 
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.
Porta C., Tortora G., Linassier C., Papazisis K., Awada A., Berthold D., Maroto J.P., Powles T., De Santis M., 2012/09. Medical oncology, 29 (3) pp. 1896-1907. Peer-reviewed.
[DOI][Pmid][serval:BIB_E1736D587255]
 
Finasteride-related Leydig cell tumour: report of a case and literature review.
Berthold D., Lhermitte B., Uffer M., Doerfler A., 2012/05. Andrologia, 44 Suppl 1 pp. 836-837.
[DOI][Pmid][serval:BIB_7B6FF11E52D6]
Avancées recentes dans le traitement des carcinomes corticosurrénaliens [Recent advances in the treatment of adrenocortical carcinomas].
Ducry J., Berthold D., Pralong F., 2012. Revue Médicale Suisse, 8 (362) pp. 2181-4, 2186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_29943BAF3051]
 
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Cathomas R., Rothermundt C., Klingbiel D., Bubendorf L., Jaggi R., Betticher D.C., Brauchli P., Cotting D., Droege C., Winterhalder R. et al., 2012. Clinical Cancer Research, 18 (21) pp. 6049-6057. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39D6FCC8E3FC]
Relapsed seminoma during surveillance: first treatment choice should be radiotherapy.
Herrera F., Berthold D.R., 2012. Journal of Clinical Oncology, 30 (16) pp. 2021; author reply 2022. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_121A7BF04541]
2011
 
Pharmacotherapeutic management of locally advanced prostate cancer: current status.
Martin J.M., Supiot S., Berthold D.R., 2011/05/28. Drugs, 71 (8) pp. 1019-1041. Peer-reviewed.
[DOI][Pmid][serval:BIB_D44530F21289]
 
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
Sturgeon J.F., Moore M.J., Kakiashvili D.M., Duran I., Anson-Cartwright L.C., Berthold D.R., Warde P.R., Gospodarowicz M.K., Alison R.E., Liu J. et al., 2011/04. European urology, 59 (4) pp. 556-562. Peer-reviewed.
[DOI][Pmid][serval:BIB_89388913C316]
A man presenting headache and photophobia while receiving BEP chemotherapy
Digklia A., Berthold D., 2011. Schweizer Krebs Bulletin = Bulletin Suisse du Cancer, 31 (2) pp. 174-176.
[URN][serval:BIB_33AB6257B43D]
 
Chemotherapy for castration-resistant prostate cancer
Berthold D., 2011. p. 12 dans Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Onkologie.
[WoS][serval:BIB_7595752110D3]
 
Das Prostatakarzinom im Wandel Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität
Cathomasa R., Berthold D., Gillessenc S., Reckerd F., Stennere F., Strebelf R., Sulserg T., Zwahlenh D.R., Schmidi H.P., 2011. Schweizerisches Medizin-Forum, 11 (43) pp. 759-763.
[URN][serval:BIB_C35C579B00F1]
ECCLU 2011 Oncologie génito-urinaire abordée par une approche multidisciplinaire ECCLU 2011: Oncologie génito-urinaire abordée par une approche multidisciplinaire
Berthold D., 2011. Leading Opinions Hämatologie und Onkologie 6 pp. 42-43.
[URN][serval:BIB_662C50C6C58C]
 
Estimation of Radiation Dose and Cancer Risk Following Diagnostic and Therapeutic Radiation Exposure in Stage I Seminoma Patients
Herrera F., Heym L., Le Coultre R., Joosten A., Verdun F., Moeckli R., Ozsahin M., Berthold D., 2011. dans SASRO 2011, Scientific Association of Swiss Radiation Oncology.
[serval:BIB_D04377227508]
 
Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K., Berthold D.R., 2011/01. Anti-cancer drugs, 22 Suppl 1 pp. S4-8. Peer-reviewed.
[DOI][Pmid][serval:BIB_73800E4C3E9E]
 
PSA Screeing : Is it a question of life or death?
Berthold D., 2011. Schweizer Krebs Bulletin = Bulletin Suisse du Cancer, 31 (4) pp. 292-294.
[URN][serval:BIB_CFFE3D8E3EB1]
 
Secondary Cancer Risk for Stage 1 Seminoma Patients : a Comparaison of Adjuvant Treatments Versus Surveillance
Berthold D., Heym L., Le Coultre R., Joosten A., Verdun F., Moeckli R., Ozsahin M., Herrera F., 2011. dans ESMO 2011, European Society for Medical Oncology.
[serval:BIB_B35D45B17F5B]
 
Secondary Cancer Risk for Stage I Seminoma Patients - a Comparison of Adjuvant Treatment Versus Surveillance
Berthold D., Heym L., Le Coultre R., Joosten A., Verdun F., Moeckli R., Ozsahin M., Herrera F., 2011. pp. S511 dans European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, European Journal of Cancer. Peer-reviewed.
[WoS][serval:BIB_B5325D985752]
 
Surveillance active du cancer de la prostate [Active surveillance in prostate cancer].
Valerio M., Vaucher L., Cerantola Y., Berthold D., Herrera F.G, Jichlinski P., 2011. Revue Médicale Suisse, 7 (320) pp. 2388-2391. Peer-reviewed.
[Pmid][serval:BIB_03B22396178D]
2010
 
Quels nouveaux médicaments a l'horizon pour te traitement du cancer avancé de la prostate? [New drugs at the horizon for men with prostate cancer]
Shabafrouz K., Bauer J., Berthold D.R., 2010/05/26. Revue medicale suisse, 6 (250) pp. 1057-1058,1060-1061. Peer-reviewed.
[Pmid][serval:BIB_944AB2211326]
 
Bone metastases of prostatic cancer : pathophysiology, clinical complications, actual treatment and future directions
De Dosso S., Herrera F.G., Berthold D.R., 2010. pp. - dans Heymann D. (eds.) Bone cancer : progression and therapeutic approaches chap. 37, Elsevier/Academic Press.
[serval:BIB_FEE8C46A3ADA]
 
Cetuximab In Combination With Docetaxel In Patients (Pts) With Metastatic Castration Resistant (Mcrpc) And Docetaxel-Refractory Prostate Cancer: Final Analysis Of The Multicenter Phase Ii Trial Sakk 08/07
Cathomas R., Rothermundt C., von Moos R., Betticher D.C., Winterhalder R., Droege C., Siciliano D., Berthold D.R., Pless M., Gillessen S., 2010. p. 276 dans 35th European-Society-for-Medical-Oncology (ESMO) Congress, Annals Of Oncology.
[WoS][serval:BIB_98B95236E5C8]
 
Ossäre Metastasen beim Prostatakarzinom
Berthold D., 2010. AP Onkologie, 2 pp. 15-17.
[serval:BIB_5C1D6CD5DACF]
Third consensus on medical treatment of metastatic breast cancer.
Berthold Dominik, 2010. Annals of Oncology, 21 (3) pp. 665; author reply 655-665; author reply 656.
[URN][DOI][WoS][Pmid][serval:BIB_0DF84D03769F]
2009
Dépistage du cancer de la prostate: actualité [Prostate cancer screening: an update]
Tawadros T., Doerfler A., Treuthardt C., Praz V., Levi F., Zouhair A., Berthold D., Bauer J., Iselin C., Jichlinski P., 2009/12/02. Revue medicale suisse, 5 (228) pp. 2438-2441. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_11E9631D48D2]
 
The transition from phase II to phase III studies.
Berthold D.R., Gulamhusein A., Jackson J.I., Tannock I.F., 2009/03/01. Journal of clinical oncology , 27 (7) pp. 1150-1151. Peer-reviewed.
[DOI][Pmid][serval:BIB_B6EB6AF0C8F9]
 
Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors.
Cheng E., Berthold D.R., Moore M.J., Duran I., 2009. Acta oncologica, 48 (3) pp. 475-477. Peer-reviewed.
[DOI][Pmid][serval:BIB_634784F7DF09]
 
La surveillance active dans la prise en charge du cancer de la prostate précoce. [Active surveillance for early-stage prostate cancer]
Jichlinski P., Berthold D. R., Zouhair A., Griesser A. C., Meuwly J. Y., Prior J. O., Lhermitte B., Doerfler A., Treuthardt C., Praz V. et al., 2009. Revue médicale suisse, 5 (228) pp. 2442-4, 2446-7.
[Pmid][serval:BIB_66220A2D6BE9]
2008
 
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Berthold D.R., Pond G.R., de Wit R., Eisenberger M., Tannock I.F., TAX 327 Investigators, 2008/10. Annals of oncology, 19 (10) pp. 1749-1753. Peer-reviewed.
[DOI][Pmid][serval:BIB_2471EDE29414]
 
Docetaxel in the management of prostate cancer: current standard of care and future directions.
De Dosso S., Berthold D.R., 2008/08. Expert opinion on pharmacotherapy, 9 (11) pp. 1969-1979. Peer-reviewed.
[DOI][Pmid][serval:BIB_317EBFF5DFFB]
 
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., Tannock A.I., TAX-327 investigators, 2008/05/01. Clinical cancer research, 14 (9) pp. 2763-2767. Peer-reviewed.
[DOI][Pmid][serval:BIB_CA7646E40C03]
 
Sorafenib for metastatic renal cancer: the Princess Margaret experience.
Riechelmann R.P., Chin S., Wang L., Tannock I.F., Berthold D.R., Moore M.J., Knox J.J., 2008/04. American journal of clinical oncology, 31 (2) pp. 182-187. Peer-reviewed.
[DOI][Pmid][serval:BIB_5317EA98FFC1]
 
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F., 2008/01/10. Journal of clinical oncology, 26 (2) pp. 242-245. Peer-reviewed.
[DOI][Pmid][serval:BIB_46DD9B6E4B76]
2007
 
Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma.
Saletti P., Berthold D., Ghielmini M., Zucca E., Fazio N., Goldhirsch A., Cavalli F., 2007. Hepato-gastroenterology, 54 (75) pp. 969-972. Peer-reviewed.
[Pmid][serval:BIB_3472926D330F]
 
Eyelid metastasis from mediastinal teratoma with malignant transformation.
Duran I., Riveros L., Berthold D.R., Sweet J., Moore M.J., 2007. Acta oncologica (Stockholm, Sweden), 46 (8) pp. 1200-1201. Peer-reviewed.
[DOI][Pmid][serval:BIB_B308D837916D]
2006
 
Targeting metastatic prostate cancer: the search for innovative systemic therapies.
Berthold D.R., Moore M.J., 2006/12. Oncology (Williston Park, N.Y.), 20 (14) pp. 1787-91; discussion 1791-6. Peer-reviewed.
[Pmid][serval:BIB_6D02A35AE285]
 
Novel targets in prostate cancer.
Berthold D.R., Moore M.J., 2006/10. Expert opinion on therapeutic targets, 10 (5) pp. 777-780. Peer-reviewed.
[DOI][Pmid][serval:BIB_BE32B20480B5]
 
Are prostate cancer clinical trial enrollment criteria and endpoints appropriate?
Berthold D.R., Tannock I.F., 2006/02. Nature clinical practice. Oncology, 3 (2) pp. 74-75. Peer-reviewed.
[DOI][Pmid][serval:BIB_4C1D9213331B]
2005
 
Management of advanced prostate cancer after first-line chemotherapy.
Berthold D.R., Sternberg C.N., Tannock I.F., 2005/11/10. Journal of clinical oncology, 23 (32) pp. 8247-8252. Peer-reviewed.
[DOI][Pmid][serval:BIB_DA74BAD0A9E9]
2004
Treatment of malignant lymphoma.
Berthold D., Ghielmini M., 2004/08/21. Swiss medical weekly, 134 (33-34) pp. 472-480. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_976AAF3364F7]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University